The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia

This study tests the safety and effectiveness of a CAR-T cell therapy (called RD06-03) — where a patient's own immune cells are genetically engineered to attack leukemia — for people with relapsed or refractory acute B-cell lymphoblastic leukemia (B-ALL), a type of blood cancer. **You may be eligible if...** - You are between 3 and 70 years old - You have been diagnosed with B-cell ALL and your cancer has either relapsed (come back) or did not respond to standard chemotherapy (refractory) - You meet specific criteria for relapse (e.g., cancer returned within 12 months after first remission) or refractory disease (e.g., failed 2 cycles of standard treatment) - Your general health and organ function are adequate **You may NOT be eligible if...** - You are under 3 or over 70 years old - Your leukemia is not the B-cell type - You do not meet the relapsed or refractory criteria - You have serious organ dysfunction or infections that cannot be controlled Talk to your doctor to see if this trial is right for you.